/
EOLS
$7.13+$0.00 (+0.00%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$469.5M
66M shares
52-week range
$3.86 – $10.20
52% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.42%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-5.52
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $34.9M | $56.5M | $99.7M | $148.6M | $202.1M | $266.3M | $297.2M |
| Cost of revenue | $9.0K | $8.0M | $18.3M | $43.5M | $58.8M | $61.6M | $84.0M | $104.4M |
| Gross profit | −$9.0K | $26.9M | $38.2M | $56.1M | $89.8M | $140.5M | $182.3M | $192.8M |
| Gross margin | — | 77.1% | 67.6% | 56.3% | 60.4% | 69.5% | 68.5% | 64.9% |
| R&D | $6.5M | $4.0M | $1.7M | $2.1M | $6.7M | $15.4M | $9.2M | $9.6M |
| Operating income | −$46.1M | −$98.9M | −$153.1M | −$44.4M | −$65.3M | −$49.2M | −$34.4M | −$37.6M |
| EBITDA | −$46.1M | −$92.1M | −$144.8M | −$39.1M | −$53.9M | −$41.8M | −$25.0M | −$22.5M |
| Net income | −$46.9M | −$90.0M | −$163.0M | −$46.8M | −$74.4M | −$61.7M | −$50.4M | −$51.6M |
| Net margin | — | -257.8% | -288.3% | -47.0% | -50.1% | -30.5% | -18.9% | -17.4% |
| EPS (diluted) | -1.92 | -3.19 | -4.83 | -0.94 | -1.33 | -1.08 | -0.81 | -0.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $330M | $-0.09 | $-0.09–$-0.08 | 4 |
| 2027 | $388M | $0.27 | $0.22–$0.31 | 4 |
| 2028 | $459M | $0.67 | $-0.36–$1.19 | 6 |
| 2029 | $528M | $1.14 | $1.12–$1.16 | 4 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$9.90
Price
$7.13
Implied upside
+39%
Peer comparison
Evolus, Inc. Common Stock
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
www.evolus.com- Employees
- 350
- IPO / List date
- Feb 8, 2018
- HQ
- NEWPORT BEACH, CA
Held by traders on TradeandTell
No one on the platform currently holds EOLS.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 339,025 | $1.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded EOLS yet.
